Gregory Riely
格雷戈里·里利
MD, PhD
Vice Chair for Clinical Research, Thoracic Oncology Service胸部肿瘤服务临床研究副主任
👥Biography 个人简介
Dr. Gregory Riely is a thoracic oncologist at MSK and a leading authority on rare EGFR mutations and resistance mechanisms in NSCLC. His work on EGFR exon 20 insertions and osimertinib resistance has shaped molecular testing paradigms and therapeutic sequencing for patients with oncogene-driven lung cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EGFR Exon 20 Insertions & Osimertinib Resistance
Defined the molecular landscape of EGFR exon 20 insertion mutations and characterized mechanisms of acquired resistance to osimertinib, informing treatment strategies beyond first-line EGFR-directed therapy.
Representative Works 代表性著作
Molecular characteristics and clinical outcomes of EGFR exon 20 insertion mutations in lung adenocarcinoma
Journal of Thoracic Oncology (2021)
Comprehensive MSK cohort analysis establishing clinical-molecular correlates of EGFR exon 20 insertions and supporting development of amivantamab and mobocertinib.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 格雷戈里·里利 的研究动态
Follow Gregory Riely's research updates
留下邮箱，当我们发布与 Gregory Riely（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment